GluK2 is a target for gene therapy in drug-resistant Temporal Lobe Epilepsy
Céline Boileau, Séverine Deforges, Angélique Peret, Didier Scavarda, Fabrice Bartoloméi, April R. Giles, Nicolas Partouche, Justine Gautron, Julio Viotti, Haley N. Janowitz, Guillaume Penchet, Cécile Marchal, Stanislas Lagarde, Agnès Trébuchon, Nathalie Villeneuve, , Valérie Crépel
This study demonstrates that gene therapy targeting GluK2 reduces seizures in TLE models and patient-derived slices.
Annals of Neurology · Jun 21, 2023Peer-reviewedNeuroscience